{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:54:35Z","timestamp":1788792875602,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Cardiology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ajpc.2022.100317","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T20:55:52Z","timestamp":1642452952000},"page":"100317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["HbA1c, Coronary atheroma progression and cardiovascular outcomes"],"prefix":"10.1016","volume":"9","author":[{"given":"Iryna","family":"Dykun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Bayturan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir R.","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Murat","family":"Tuzcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Puri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpc.2022.100317_bib0001","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/cd21-as01","article-title":"Standards of medical care in diabetes-2021 abridged for primary care providers","volume":"39","author":"American Diabetes A","year":"2021","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.ajpc.2022.100317_bib0002","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0895-4356(95)00513-7","article-title":"Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study","volume":"49","author":"Meigs","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ajpc.2022.100317_bib0003","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ajpc.2022.100317_bib0004","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/dci16-0042","article-title":"Hemoglobin A1c and mortality in older adults with and without diabetes: results from the national health and nutrition examination surveys (1988-2011)","volume":"40","author":"Palta","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2022.100317_bib0005","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/archinte.165.16.1910","article-title":"Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study","volume":"165","author":"Selvin","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajpc.2022.100317_bib0006","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa0908359","article-title":"Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults","volume":"362","author":"Selvin","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2022.100317_bib0007","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12933-021-01413-4","article-title":"Association of glycated hemoglobin A1c levels with cardiovascular outcomes in the general population: results from the BiomarCaRE (Biomarker for Cardiovascular Risk Assessment in Europe) consortium","volume":"20","author":"Sinning","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ajpc.2022.100317_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2022.100317_bib0009","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/archinternmed.2009.551","article-title":"The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis","volume":"170","author":"Bayturan","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ajpc.2022.100317_bib0010","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1093\/eurheartj\/ehy209","article-title":"Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes","volume":"39","author":"Clark","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ajpc.2022.100317_bib0011","article-title":"High-risk coronary plaque regression after intensive lifestyle intervention in nonobstructive coronary disease: a randomized study","author":"Henzel","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ajpc.2022.100317_bib0012","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.2337\/dc14-1121","article-title":"High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN","volume":"37","author":"Stegman","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ajpc.2022.100317_bib0013","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2022.100317_bib0014","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2022.100317_bib0015","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.ajpc.2022.100317_bib0016","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"10.1016\/j.ajpc.2022.100317_bib0017","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2022.100317_bib0018","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial","volume":"310","author":"Nicholls","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2022.100317_bib0019","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.299.13.1547","article-title":"Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2022.100317_bib0020","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ajpc.2022.100317_bib0021","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.jacc.2005.12.058","article-title":"Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound","volume":"47","author":"Nicholls","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajpc.2022.100317_bib0022","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mje.2003.45","article-title":"Variability of area measurements obtained with different intravascular ultrasound catheter systems: Impact on clinical trials and a method for accurate calibration","volume":"16","author":"Schoenhagen","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.ajpc.2022.100317_bib0023","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1253\/circj.CJ-11-1495","article-title":"Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study","volume":"76","author":"Takashima","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.ajpc.2022.100317_bib0024","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10554-011-9882-6","article-title":"Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis","volume":"28","author":"Garcia-Garcia","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.ajpc.2022.100317_bib0025","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpc.2022.100317_bib0026","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.ajpc.2022.100317_bib0027","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcin.2020.10.008","article-title":"Hemoglobin A1c and cardiovascular outcomes following percutaneous coronary intervention: insights from a large single-center registry","volume":"14","author":"Baber","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ajpc.2022.100317_bib0028","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1016\/j.jacc.2021.03.335","article-title":"Glycated hemoglobin and subclinical atherosclerosis in people without diabetes","volume":"77","author":"Rossello","year":"2021","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667722000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666667722000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:35:41Z","timestamp":1763004941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666667722000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"alternative-id":["S2666667722000046"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpc.2022.100317","relation":{},"ISSN":["2666-6677"],"issn-type":[{"value":"2666-6677","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HbA1c, Coronary atheroma progression and cardiovascular outcomes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpc.2022.100317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100317"}}